Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 7/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.40 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.39 |
| ▸ | ADH5 | P11766 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15761243 | 0.82 | S1PR1 (0.47) | S1PR1S1PR3FFAR2AKR1C3AKR1C2 | |
| SCHEMBL17134195 | 0.82 | S1PR1 (0.47) | S1PR1S1PR3FFAR2AKR1C3AKR1C2 | |
| SCHEMBL403135 | 0.81 | AKR1C3 (0.55) | S1PR1FFAR2AKR1C3AKR1C2ADH5 | |
| SCHEMBL13130059 | 0.80 | PTGS1 (0.42) | AKR1C3AKR1C2TSHR | |
| SCHEMBL2812066 | 0.80 | PTGS1 (0.42) | AKR1C3AKR1C2TSHR | |
| SCHEMBL402398 | 0.78 | ADH5 (0.58) | S1PR1FFAR2AKR1C3AKR1C2ADH5 | |
| SCHEMBL27702486 | 0.78 | AKR1C3 (0.50) | S1PR1S1PR3FFAR2AKR1C3AKR1C2 | |
| SCHEMBL23865026 | 0.76 | MAPT (0.44) | GAANPC1RAB9A | |
| SCHEMBL17654424 | 0.76 | MAPT (0.44) | GAANPC1RAB9A | |
| SCHEMBL12391627 | 0.76 | KDM1A (0.43) | GAANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644367-B1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | NOVARTIS AG (CH) | 2015-10-14 | — | — | EP | disclosed |
| CN-102174042-B | Immunosuppressant compounds and compositions | IRM LLC | 2013-09-18 | — | — | CN | disclosed |
| CN-102174042-A | Immunosuppressant compounds and compositions | IRM LLC | 2011-09-07 | — | — | CN | disclosed |
| CN-1816544-B | Immunosuppressant compounds and compositions | IRM LLC | 2011-06-08 | — | — | CN | disclosed |
| EP-2233473-A1 | 3,5-di(aryl or heteroaryl)isoxazoles and 1,2,4-oxadiazoles as S1P1 receptor agonists, immunosuppresssive and anti-inflammatory agents | Novartis AG (CH) | 2010-09-29 | — | — | EP | disclosed |
| US-7799812-B2 | Reverse isoxazoles | NOVARTIS AG (CH) | 2010-09-21 | — | — | US | disclosed |
| EP-1981858-B1 | 3,5-DI(ARYL OR HETEROARYL)ISOXAZOLES AND 1,2,4-OXADIAZOLES AS S1P1 RECEPTOR AGONISTS, IMMUNOSUPPRESSSIVE AND ANTI-INFLAMMATORY AGENTS | NOVARTIS AG (CH) | 2010-06-16 | — | — | EP | disclosed |
| US-20090137636-A1 | Reverse Isoxazoles | NOVARTIS AG | 2009-05-28 | — | — | US | disclosed |
| CN-101374821-A | 3,5-di(aryl or heteroaryl)isoxazoles and 1,2,4-oxadiazoles as S1P1 receptor agonists, immunosuppresssive and anti-inflammatory agents | NOVARTIS AG (CH) | 2009-02-25 | — | — | CN | disclosed |
| EP-1644367-A4 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2008-12-31 | — | — | EP | disclosed |
| US-7462629-B2 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2008-12-09 | — | — | US | disclosed |
| EP-1981858-A2 | 3,5-DI(ARYL OR HETEROARYL)ISOXAZOLES AND 1,2,4-OXADIAZOLES AS S1P1 RECEPTOR AGONISTS, IMMUNOSUPPRESSSIVE AND ANTI-INFLAMMATORY AGENTS | Novartis AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007085451-A2 | 3,5-DI (ARYL OR HETEROARYL) ISOXAZOLES AND 1, 2, 4-OXADIAZOLES AS S1P1 RECEPTOR AGONISTS, IMMUNOSUPPRESSSIVE AND ANTI -INFLAMMATORY AGENTS | NOVARTIS AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| CN-1816544-A | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2006-08-09 | — | — | CN | disclosed |
| EP-1644367-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2006-04-12 | — | — | EP | disclosed |
| US-20050009786-A1 | Immunosuppressant compounds and compositions | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2005-01-13 | — | — | US | disclosed |
| WO-2004113330-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137636-A1 | Reverse Isoxazoles | CYP3A7, CYP3A4, TBXA2R | S1PR1 3804/4885S1PR3 2578/4885FFAR2 2188/4885 |
| US-20050009786-A1 | Immunosuppressant compounds and compositions | ICOS, EDNRA, NFATC1 | S1PR1 133/4885S1PR3 142/4885FFAR2 687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.